Endo Says FTC Is Overreacting To Latest Impax Opioid Deal
By Isaac Monterose · April 27, 2021, 9:43 PM EDT
Endo Pharmaceuticals is pushing for the dismissal of a Federal Trade Commission antitrust suit alleging it entered a second "pay-for-delay" agreement with Impax Laboratories over Endo's Opana ER painkiller, arguing the...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login